Healio | HemOnc Today announces new physician leadership
Click Here to Manage Email Alerts
Healio | HemOnc Today is excited to announce a new physician leadership structure, which features seven Associate Medical Editors from various subspecialty areas within oncology and hematology.
The new senior leadership board — which will guide Healio | HemOnc Today ’s Editorial Board — will assist in content selection and act as ambassadors for the publication.
“Staying on top of the issues of interest to our readers requires close collaboration with the experts,” said Joan-Marie Stiglich, ELS, Healio’s Chief Content Officer. “Our goal with the new leadership design is to provide broad specialty and subspecialty coverage of issues and topics of importance to the oncology and hematology communities.”
Joining Healio | HemOnc Today as Associate Medical Editors are:
• Charu Aggarwal, MD, MPH, Leslye Heisler associate professor for lung cancer excellence at University of Pennsylvania’s Perelman School of Medicine, associate director for Penn Center for Precision Medicine and associate director of Penn Center for Cancer Care Innovation.
Aggarwal specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of personalized therapeutic approaches, and the discovery and application of biomarkers to guide treatment.
Aggarwal has been a member of the Healio | HemOnc Today Editorial Board member since 2018.
• Adam M. Brufsky, MD, PhD, is professor of medicine at University of Pittsburgh School of Medicine and associate director for strategic initiatives at UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania.
He is co-director of the Comprehensive Cancer Center of UPMC Hillman Cancer Center, as well as medical director of the cancer center's Magee-Women's Cancer Program.
Brufsky’s primary clinical interest is breast cancer medical oncology. His research focuses on novel clinical therapeutics, molecular biology of and novel management strategies for metastatic disease, and bone-breast cancer interactions.
Brufsky has been a Healio | HemOnc Today Editorial Board member since 2010.
• Jonathan M. Gerber, MD, chief of hematology and oncology, cancer center director and Eleanor Eustis Farrington chair in cancer research at UMass Chan Medical School and UMass Memorial Health.
Gerber conducts translational research in leukemia with a focus on leukemia stem cells, including identification and targeting, minimal residual disease assays, and phenotype and response. He also focuses on early-phase clinical investigation, including research on novel agents to target leukemia stem cells, predictors of response, and lab correlates of clinical trials.
Gerber has been a member of the Healio | HemOnc Today Editorial Board since 2014.
• Petros Grivas, MD, PhD, a board-certified medical oncologist with expertise in genitourinary cancers.
He is clinical director of the GU Cancers program and professor in the department of medicine within the division of medical oncology at University of Washington, and in the clinical research division at Fred Hutchinson Cancer Center.
Grivas has had a main role in several clinical trials that led to FDA approval of new drugs for urothelial cancer.
He received the NextGen Disruptor Award in the Healio Disruptive Innovators Awards program in 2022.
• Shikha Jain, MD, FACP, associate professor of medicine with tenure in the division of hematology, oncology and cell therapy at University of Illinois Cancer Center in Chicago.
Jain is founder, CEO and president of Women in Medicine, as well as founder and chair of the Women in Medicine Summit.
She specializes in treatment of colorectal cancer, neuroendocrine tumors and hepatocellular carcinoma.
Jain has been a member of the Healio | HemOnc Today Editorial Board since 2020.
She is consulting editor for Healio Women in Oncology, as well as host of Healio's Oncology Overdrive podcast. She also is co-host of the annual Healio Disruptive Innovators Awards ceremony, which recognizes clinicians in oncology/hematology who have changed the face of the specialty and pushed the status quo toward betterment of the field.
• Edward S. Kim, MD, MBA, FACP, FASCO, physician-in-chief for City of Hope Orange County and vice physician-in-chief for City of Hope National Medical Center.
Kim is recognized for his expertise in molecular prognostication for lung cancer, as well as head and neck cancer.
Kim has been a member of the Healio | HemOnc Today Editorial Board since 2014.
He develops content for the immuno-oncology and genomics modules within Clinical Guidance, a point-of-care tool on Healio that offers health care providers with reliable information to make clinical decisions in a quick and efficient manner. He also is co-host of the annual Healio Disruptive Innovators Awards ceremony.
• Marcela V. Maus, MD, PhD, director of the cellular immunotherapy program at Mass General Cancer Center and associate professor of medicine at Harvard Medical School.
Maus also is affiliated with the cancer immunology and lymphoma/myeloma programs at Dana-Farber/Harvard Cancer Center.
Her lab designs and evaluates cellular therapies to treat patients with hematologic malignancies or solid tumors, with an emphasis on immune biomarkers, the mechanisms of immunotherapy, potential toxicities and causes of relapse.
Her current research work includes basic and translational immunotherapies targeting lymphoma, myeloma, acute myeloid leukemia, glioblastoma and pancreatic cancer.
Maus is a founding member of the peer perspective board for Healio | Cell Therapy Next, which focuses on advances in chimeric antigen receptor T-cell therapy and other cellular therapies.
“Healio has always been at the forefront of getting up-to-date innovative information out to a large audience, which I find refreshing at a time when we are constantly bombarded with misinformation,” Jain said. “I appreciate the work Healio does covering cutting-edge medicine and health care, as well as policy and equity efforts, and the impact all of these have on the intersection of our health care systems.”
The new senior leadership board succeeds Chief Medical Editors Emeritus Derek Raghavan, MD, PhD, and John Sweetenham, MD. Healio | HemOnc Today is grateful for their leadership while serving as Chief Medical Editors and their continued support.
Collapse
Press Release
Click Here to Manage Email Alerts